Halina Bartosik-Psujek

Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial

Benedikt Schoser, Mark Roberts, Barry J. Byrne et al. · The Lancet Neurology · 2021 · 132 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +3

Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients

Konrad Rejdak, Halina Bartosik-Psujek, B Dobosz et al. · Neuroscience Letters · 2002 · 111 citations

Life Sciences, Neurology, Neuroscience +6

The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease

Halina Bartosik-Psujek, Z Stelmasiak · European Journal of Neurology · 2004 · 101 citations

Life Sciences, Clinical Sciences, Immunology +17

Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG

Halina Bartosik-Psujek, Juan J. Archelos · Journal of Neurology · 2004 · 68 citations

Life Sciences, Neurology, Neuroscience +14

Interleukin-6 concentration in serum and cerebrospinal fluid in multiple sclerosis patients.

Zbigniew Stelmasiak, Maria Kozioł-Montewka, B Dobosz et al. · PubMed · 2001 · 64 citations

Life Sciences, Immunology, Neurology +16